Lifecore Biomedical/Iolab
This article was originally published in The Gray Sheet
Executive Summary
Sign letter of understanding whereby Lifecore would supply the Johnson & Johnson subsidiary with ophthalmic sodium hyaluronate for its Amvisc and Amvisc Plus viscoelastic solutions through Dec. 31, 2000. Under the agreement, expected to be finalized in a month to six weeks, Lifecore will manufacture raw material powder and finished sterile-filled syringe forms of the two products, the firm explains. Iolab "would be granted exclusive rights to certain molecular weight ranges of Lifecore's hyaluronate for use in ophthalmic viscoelastic solutions" that are not expected to be in full commercialization until 1997. Lifecore and Iolab already have a research and development agreement relating to high molecular weight hyaluronate
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.